Diltiazem and MK-801 but not APV Act Synergistically to Protect Rat Hippocampal Slices against Hypoxic Damage

  • Avital Schurr
  • Ralphiel S. Payne
  • Benjamin M. Rigor
Part of the GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia book series (GWUN)


The noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 {(+)-5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine maleate, dizocilpine} potently protects hippocampal slices against hypoxic neuronal damage, while the competitive NMDA receptor antagonist 2-amino-5-phosphonovalerate (APV) has a much weaker neuroprotective potency.1,2 In addition, MK-801 protects hippocampal slices against the combined effects of hypoxia + NMDA, and hypoxia + kainate (KA) or α-amino-3-hydroxy-5-methyl-4-isoxazolpropionate (AMPA). Furthermore, MK-801 was found to be a better antagonist of KA (or AMPA)-enhanced hypoxic neuronal damage than the specific KA/AMPA antagonist GYKI 52466 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine HC1]. The combination of APV and 7-chlorokynurenate could not abolish the protective effect of MK-801 against hypoxia, a effect one should expect if MK-801 exerts its protective action via an open NMDA receptor.3 Thus, at least in the continuously-perfused hippocampal slice preparation, where hypoxiainduced glutamate accumulation cannot reach excitotoxic levels, the antihypoxic effect of MK-801 does not appear to be mediated through the NMDA receptor. Several other recent studies also raise questions in regard to MK-801 mode of action. One study4 concluded that ketamine, an anesthetic known to compete for MK-801 binding sites,5 is an inhibitor of L-type calcium channels, while another study6 points to both similarities and differences between these two compounds depending on the method of administration of ketamine. Yet, another study7 demonstrated the ability of diltiazem (DILT), an L-type calcium channel blocker,8–10 to inhibit [3H]MK-801 binding to hippocampal synaptic membranes at IC50 value which is very similar to the IC50 of unlabelled MK-801. These studies, along with our own results that showed DILT to provide a significant protection against hypoxia-induced neuronal damage,1 led us to suggest that MK-801 may possess L-type calcium channel blocking properties.


NMDA Receptor Hippocampal Slice Dual Chamber Diltiazem Hydrochloride Reoxygenation Period 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Schurr, R.S. Payne and B.M. Rigor, Protection by MK-801 against hypoxia-, excitotoxin-, and depolarization-induced neuronal damage in vitro, Neurochem. Int. (in press).Google Scholar
  2. 2.
    P.G. Aitken, M. Balestrino and G.G. Somjen, NMDA antagonists: lack of protective effect against hypoxic damage in CA1 region of hippocampal slices, Neurosci. Lett. 89:187–192 (1988).PubMedCrossRefGoogle Scholar
  3. 3.
    J.E. Huettner and B.P. Bean, Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels, Proc. Natl. Acad. Sci. USA 85:1303–1311 (1988).CrossRefGoogle Scholar
  4. 4.
    P.H. Ratz, P.E. Callahan and F.A. Lattanzio, Ketamine relaxes rabbit femoral arteries by reducing [Ca2+]j and phospholipase C activity, Eur. J. Pharmacol. 236:433–441 (1993).PubMedCrossRefGoogle Scholar
  5. 5.
    E.H.F. Wong, J.A. Kemp, T. Priestley, A.R. Knight, G.N. Woodruff and L.L. Iversen, The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist, Proc. Natl. Acad. Sci. USA 83:7104–7108 (1986).PubMedCrossRefGoogle Scholar
  6. 6.
    M.D. Kelland, R.P. Soltis, R.C. Boldry and J.R. Walters, Behavioral and electrophysiological comparison of ketamine with dizocilpine in the rat, Physiol. Behav. 54:547–554 (1993).PubMedCrossRefGoogle Scholar
  7. 7.
    M. Maruyama and K. Takeda, Electrophysiologically potent non-competitive glutamate antagonists at crayfish neuromuscular junctions are also potent inhibitors of [3H]MK-801 binding to synaptic membranes from rat central nervous system, Comp. Biochem. Physiol. 107C: 105–110 (1994).Google Scholar
  8. 8.
    S. Actachi-Akahane and T. Nagao, Binding site for diltiazem is on the extracellular side of the L-type Ca2+ channel, Circulation 88:1–230 (1993).Google Scholar
  9. 9.
    K.J. Brooks and R.A. Kauppinen, Calcium-mediated damage following hypoxia in cerebral cortex ex vivo studied by NMR spectroscopy. Evidence for direct involvement of voltage-gated Ca2+-channels, Neurochem. Int. 23:441–450 (1993).PubMedCrossRefGoogle Scholar
  10. 10.
    D. Uematsu, N. Araki, J.H. Greenberg, J. Sladky and M. Reivich, Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage, Neurology 41:88–94 (1991).PubMedCrossRefGoogle Scholar
  11. 11.
    A. Schurr, K.H. Reid, M.T. Tseng, H.L. Edmonds, Jr. and B.M. Rigor, A dual chamber for comparative studies using the brain slice preparation, Comp. Biochem. Physiol. 82A:701–705 (1985).CrossRefGoogle Scholar
  12. 12.
    A. Schurr, P. Lipton, C.A. West and B.M. Rigor, The role of energy metabolism and divalent cations in the neurotoxicity of excitatory amino acids in vitro, in: Pharmacology of Cerebral Ischemia 1990, J. Krieglstein and H. Oberpichler, Eds., Wissenschaftliche Verlagsgesellschaft, Stuttgart (1990) pp. 217-226.Google Scholar
  13. 13.
    A.C. Foster and E.H.F. Wong, The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain, Br. J. Pharmacol. 91:403–409 (1987).PubMedCrossRefGoogle Scholar
  14. 14.
    A.C. Foster, R. Gill, J.A. Kemp and G.N. Woodruff, Systemic administration of MK-801 prevents N-methyl-D-aspartate-induced neuronal degeneration in rat brain, Neurosci. Lett. 76:307–311 (1987).PubMedCrossRefGoogle Scholar
  15. 15.
    A.C. Foster, R. Gill and G.N. Woodruff, Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation, J. Neurosci. 8:4745–4754 (1988).PubMedGoogle Scholar
  16. 16.
    G.N. Woodruff, A.C. Foster, R. Gill, J.A. Kemp, E.H.F. Wong and L.L. Iversen, The interaction between MK-801 and receptors for N-methyl-D-aspartate: functional consequences, Neuropharmacology 26:903–909 (1987).PubMedCrossRefGoogle Scholar
  17. 17.
    T. Watanabe, H. Kalasz, H. Yabana, A. Kuniyasu, J. Mershon, K. Itagaki, P.L. Vaghy, K. Naito, H. Nakayama and A. Schwartz, Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the c1 subunit of the skeletal muscle calcium channel, FEBS Lett. 334:261–264 (1993).PubMedCrossRefGoogle Scholar
  18. 18.
    M. C. Berenbaum, What is synergy? Pharmacol. Rev. 41: 93–141 (1989).PubMedGoogle Scholar
  19. 19.
    R. Netzer, V. Graf, G. Pfimlin and G. Trube, Effects of some NMDA receptor channel antagonists on voltage-dependent Ca2+ channels in cultured cortical neurons, in: Pharmacology of Cerebral Ischemia 1990, J. Krieglstein and H. Oberpichler, Eds., Wissenschaftliche Verlagsgesellschaft, Stuttgart (1990) pp 129-137.Google Scholar
  20. 20.
    F.M. Filloux, R.C. Fitts, G.A. Skeen and H.S. White, The dihydropyrydine nitrendipine inhibits [3H]MK-801 binding to mouse brain sections, Eur. J. Pharmacol. 269:325–330 (1994).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Avital Schurr
    • 1
  • Ralphiel S. Payne
    • 1
  • Benjamin M. Rigor
    • 1
  1. 1.Department of AnesthesiologyUniversity of Louisville, School of MedicineLouisvilleUSA

Personalised recommendations